Table 3.
Patient data stratified according to HAVCR1 haplotypesa
| Cohort and characteristic | No. of patients with indicated no. of copies of each haplotype (% of total no. of patients) or indicated statistics |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A |
B |
C |
D |
|||||||||||
| 1 or 2 | 0 | P | 1 or 2 | 0 | P | 1 or 2 | 0 | P | Pc | OR (95% CI) | 1 or 2 | 0 | P | |
| Cohort 1 | ||||||||||||||
| Spontaneous viral clearance | 140 (50.00) | 140 (50.00) | 127 (45.35) | 153 (54.65) | 114 (40.71) | 166 (59.29) | 77 (27.50) | 203 (72.50) | ||||||
| Chronic hepatitis C | 38 (55.07) | 31 (44.93) | NS | 35 (50.72) | 34 (49.27) | NS | 27 (39.13) | 42 (60.87) | NS | 20 (28.98) | 49 (71.02) | NS | ||
| Sustained response | 49 (43.75) | 63 (56.25) | 49 (43.75) | 63 (56.25) | 52 (46.42) | 60 (53.58) | 28 (25.00) | 84 (75.00) | ||||||
| Nonsustained response | 59 (55.19) | 46 (43.81) | NS | 49 (46.66) | 56 (53.33) | NS | 43 (40.95) | 62 (59.05) | NS | 29 (27.61) | 76 (72.39) | NS | ||
| G1 | 107 (51.19) | 102 (48.81) | 97 (46.41) | 112 (53.89) | 96 (45.93)b | 113 (54.07) | 50 (23.92) | 159 (76.08) | ||||||
| Non-G1 | 26 (40.62) | 38 (59.38) | NS | 29 (45.31) | 35 (54.69) | NS | 17 (26.56) | 47 (73.44) | 0.006 | 0.024 | 2.35 (1.27–4.33) | 23 (35.93) | 41 (64.07) | NS |
| Cohort 2 | ||||||||||||||
| Sustained response | 34 (50.00) | 34 (50.00) | 28 (41.17) | 40 (58.83) | 25 (36.76) | 43 (63.24) | 18 (26.47) | 50 (73.53) | ||||||
| Nonsustained response | 29 (50.00) | 29 (50.00) | NS | 27 (46.55) | 31 (53.45) | NS | 22 (37.93) | 36 (62.07) | NS | 10 (17.24) | 48 (82.76) | |||
| G1 | 42 (48.83) | 44 (51.17) | 37 (43.02) | 49 (56.98) | 42 (48.83)c | 44 (51.17) | 17 (19.77) | 69 (80.23) | ||||||
| Non-G1 | 49 (51.58) | 46 (48.42) | NS | 42 (44.21) | 53 (55.79) | NS | 27 (28.42) | 68 (71.58) | 0.006 | 0.024 | 2.40 (1.30–4.43) | 26 (27.36) | 69 (72.64) | NS |
| Cohort 3 | ||||||||||||||
| Control | 177 (55.31) | 143 (44.69) | 119 (37.18) | 201 (62.81) | 108 (33.75) | 212 (66.25) | 66 (20.62) | 254 (79.37) | ||||||
| Cohorts 1 and 2 | ||||||||||||||
| Infection rate by G1 | 149 (66.51)d | 146 (63.47) | 134 (65.36)d | 161 (64.65) | 138 (75.82)e | 157 (57.72) | 67 (57.75) | 228 (67.45) | ||||||
| Infection rate by non-G1 | 75 (33.49) | 84 (36.53) | NS | 71 (34.64) | 88 (35.35) | NS | 44 (24.18) | 115 (42.28) | 8 × 10−5 | 3.2 × 10−4 | 2.30 (1.51–3.47) | 49 (42.25) | 110 (32.55) | NS |
a
Data of patients were stratified and compared according to whether the patients had spontaneous viral clearance or persistent infection, whether they had a sustained response or a nonsustained response, and whether they were infected with G1 or non-G1.
b
Compared to control values, Pc = 0.024, OR = 1.67, 95% CI = 1.17 to 2.38.
c
Compared to control values, Pc = 0.048, OR = 1.87, 95% CI = 1.16 to 3.02.
d
Using genotypes AA, AB, and BB, there were 94 (63.51%) people infected with G1 and 54 (36.49%) people infected with non-G1.
e
A comparison with genotypes AA, AB, and BB yields a P value of 0.016, a Pc value of 0.048, an OR of 1.80, and a 95% CI of 1.09 to 2.98.